Impact of Hypoglycemia Unawareness on Brain Metabolism Cognition in T1DM

This study has been completed.
Sponsor:
Collaborators:
University of Miami
University of Minnesota - Clinical and Translational Science Institute
Information provided by (Responsible Party):
Robert Sherwin, Yale University
ClinicalTrials.gov Identifier:
NCT00575783
First received: December 14, 2007
Last updated: January 25, 2012
Last verified: January 2012
  Purpose

The research study is designed to examine the impact of low blood sugar on brain function in individuals with Type 1 Diabetes who have frequent and severe hypoglycemia (low blood sugar) compared to those who do not.


Condition
Type 1 Diabetes
Hypoglycemia

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Impact of Hypoglycemia Unawareness on Brain Metabolism Cognition in T1DM

Resource links provided by NLM:


Further study details as provided by Yale University:

Estimated Enrollment: 51
Study Start Date: August 2005
Study Completion Date: August 2008
Groups/Cohorts
1A, 1B

Type 1 diabetic subjects with a history of severe hypoglycemia and hypoglycemia unawareness who:

1A) meet criteria for islet cell transplantation and are referred by a participating islet cell transplantation center

1B) meet similar criteria but are not currently planning islet cell transplantation

2
Type 1 diabetics who are not optimally controlled (>8% HbA1c) and rarely experience hypoglycemia
3
Healthy non-diabetics

Detailed Description:

During the course of treating diabetes (for example, after an insulin injection), blood sugar levels will sometimes drop too low. This condition is known as hypoglycemia. Normally, a healthy body responds to hypoglycemia by producing a number of "anti-insulin" hormones which raise blood sugar levels. In addition, these hormones provide the individual with warning signals of hypoglycemia, including hunger, sweating, shaking and heart palpitations. These warning signals allow diabetics to correct low blood sugar levels by eating sugar tablets or by having a snack.

Unfortunately, and for unclear reasons, many people with longstanding diabetes lose their ability to recognize low blood sugar levels-a condition called "hypoglycemia unawareness." The brain, in particular, is extremely sensitive to hypoglycemia. Unable to sense and respond to low blood sugar levels, these individuals may experience a sudden onset of blurred vision, confusion, seizures, coma, or even death.

In recent years, a new technique called "islet cell transplantation" has been developed as an alternate means of treating insulin-dependent diabetes. Pancreatic islet cells (the cells that produce insulin), from human donors, are injected into the diabetic patient's liver where the cells are capable of making insulin and can regulate blood sugar levels without the need for insulin injections. Currently, this technique is used primarily in patients with severe hypoglycemia unawareness.

While it is known that islet cell transplantation can reduce the risk of severe hypoglycemia, the effects of transplantation on hypoglycemia unawareness are unknown. This study is designed to investigate why hypoglycemia unawareness happens and the impact it has on brain function in individuals with type 1 diabetes.

  Eligibility

Ages Eligible for Study:   18 Years to 49 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Group 1A) T1DM subjects with severe hypoglycemia unawareness and awaiting islet cell transplantation will be referred by participating islet transplantation centers.

Group 1B) T1DM subjects with severe hypoglycemia unawareness but not awaiting islet cell transplantation will be from the greater New Haven, CT area.

Group 2)T1DM, not optimally controlled and without hypoglycemia unawareness will be from the greater New Haven, CT area.

Group 3) Non-Diabetics from the greater New Haven CT area.

Criteria

Inclusion Criteria:

  • Inclusion Criteria for all subjects:

    • Age 18-49
    • > 85 kg
    • BMI <27female <28 male
    • able to provide written informed consent
    • able to speak and read English fluently
    • must meet Magnetic Resonance safety evaluation

Inclusion criteria for Group 1A:

  • T1DM undergoing intensive clinical management and currently on the islet transplant list
  • History of severe hypoglycemia

Inclusion criteria for Group 1B:

  • T1DM undergoing intensive clinical management
  • History of severe hypoglycemia unawareness

Inclusion criteria for Group 2:

  • T1DM with poor glycemic control, HbA1c > 8%
  • no episodes of hypoglycemia requiring assistance from another person for at least 1 yr, no episodes in last 4 weeks, and hypoglycemia aware

Exclusion Criteria:

Group 1A: (T1DM subjects being considered for islet cell transplantation)

  • Detectable c-peptide level
  • Untreated proliferative retinopathy
  • Creatinine clearance < 65 ml/min/1.73 m2
  • Serum creatinine ≥1.5 mg/dL
  • Previous pancreas or islet transplant
  • Positive pregnancy test, or presently breast-feeding, or failure to follow effective contraceptive measures
  • Active infection including hepatitis C, hepatitis B, HIV, or TB (or under treatment for suspected TB ), or subjects with a positive PPD performed within 1 yr. of enrollment, and no history of adequate prophylaxis
  • Invasive aspergillus infection within year prior to study entry
  • Any history of malignancy except for adequately treated squamous or basal cell carcinoma of the skin
  • Active alcohol or substance abuse- includes cigarette smoking (must be abstinent for 6 months)
  • History of non-adherence to prescribed regimens
  • Psychiatric disorder making the subject not a suitable candidate for transplantation
  • Baseline Hgb < 10.5 g/dL in females, or < 13 g/dL in males; lymphopenia (<1,000/μL), or leukopenia (< 3,000 total leukocytes/μL), or an absolute CD4+ count < 500/μL
  • History of coagulopathy or medical condition requiring long-term anticoagulant therapy (e.g., warfarin) after transplantation (low-dose aspirin treatment is allowed) or patient with INR >1.5
  • Severe co-existing cardiac disease, as determined by referring center
  • Baseline liver function tests outside of normal range (an initial liver function test panel with any values >1.5 times normal upper limits will exclude a patient without a re-test; a re-test for any values between normal and 1.5 times normal will be made, and if the values remain elevated above normal, the patient will be excluded), or history of significant liver disease
  • Severe unremitting diarrhea or other gastrointestinal disorders potentially interfering with the ability to absorb oral medications
  • Addison's disease as determined by clinical history
  • Under treatment for a medical condition requiring chronic use of systemic steroids
  • Any medical condition or medication that, in the opinion of the investigators, will interfere with the safe completion of the study or study outcomes

Group 1 B: (T1DM with Severe Hypoglycemia Unawareness not on the Transplant List)

  • Detectable C-peptide level
  • Serum creatinine ≥1.5 mg/dL
  • Positive pregnancy test, or presently breast-feeding, or failure to follow effective contraceptive measures
  • Active alcohol or substance abuse- includes cigarette smoking (must be abstinent for 6 months)
  • Psychiatric disorder making the subject not a suitable candidate for transplantation
  • Baseline Hgb < 10.5 g/dL in females, or < 13 g/dL in males
  • Baseline liver function tests outside of normal range (an initial liver function test panel with any values >1.5 times normal upper limits will exclude a patient without a re-test; a re-test for any values between normal and 1.5 times normal will be made, and if the values remain elevated above normal, the patient will be excluded), or history of significant liver disease
  • Under treatment for a medical condition requiring chronic use of systemic steroids
  • Any medical condition or medication that, in the opinion of the investigators, will interfere with the safe completion of the study or study outcomes

Group 2: (T1DM control subjects)

  • Detectable C-peptide level
  • Serum creatinine ≥1.5 mg/dL
  • Positive pregnancy test, or presently breast-feeding, or failure to follow effective contraceptive measures
  • Any history of malignancy except for adequately treated squamous or basal cell carcinoma of the skin
  • Active alcohol or substance abuse- includes cigarette smoking (must be abstinent for 6 months)
  • Baseline Hgb < 10.5 g/dL in females, or < 13 g/dL in males Baseline liver function tests outside of normal range (an initial liver function test panel with any values >1.5 times normal upper limits will exclude a patient without a re-test; a re-test for any values between normal and 1.5 times normal will be made, and if the values remain elevated above normal, the patient will be excluded), or history of significant liver disease
  • Addison's disease as determined by clinical history
  • Under treatment for a medical condition requiring chronic use of systemic steroids
  • Any medical condition or medication that, in the opinion of the investigators, will interfere with the safe completion of the study or study outcomes

Group 3: (Normal Controls)

  • FBG > 100 mg/dL
  • Serum creatinine ≥1.5 mg/dL
  • Positive pregnancy test, or presently breast-feeding, or failure to follow effective contraceptive measures
  • Any history of malignancy except for adequately treated squamous or basal cell carcinoma of the skin
  • Active alcohol or substance abuse- includes cigarette smoking (must be abstinent for 6 months)
  • Baseline Hgb < 10.5 g/dL in females, or < 13 g/dL in males
  • Baseline liver function tests outside of normal range (an initial liver function test panel with any values >1.5 times normal upper limits will exclude a patient without a re-test; a re-test for any values between normal and 1.5 times normal will be made, and if the values remain elevated above normal, the patient will be excluded), or history of significant liver disease
  • Under treatment for a medical condition requiring chronic use of systemic steroids
  • Any medical condition or medication that, in the opinion of the investigators, will interfere with the safe completion of the study or study outcomes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00575783

Locations
United States, Connecticut
Yale University School of Medicine
New Haven, Connecticut, United States, 06520
Sponsors and Collaborators
Yale University
University of Miami
University of Minnesota - Clinical and Translational Science Institute
Investigators
Principal Investigator: Robert Sherwin, MD Yale University
  More Information

Additional Information:
No publications provided

Responsible Party: Robert Sherwin, Chief of Endocrinology, Yale University
ClinicalTrials.gov Identifier: NCT00575783     History of Changes
Other Study ID Numbers: DK72409 (completed), R01DK072409, HIC# 0505000077
Study First Received: December 14, 2007
Last Updated: January 25, 2012
Health Authority: United States: Federal Government

Keywords provided by Yale University:
type 1 diabetes
hypoglycemia
magnetic resonance imaging

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Hypoglycemia
Unconsciousness
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Consciousness Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on August 21, 2014